Company Profile
Werewolf Therapeutics Stock Price, News & Analysis
- Ticker:
- HOWL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.40 USD (+0.20%)
Close
Last updated: August 6, 2026
20.9M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, HOWL was little changed and closed at $0.4028. No new same-company headline was identified in the current news window.
Company overview
Conditionally Activated Immunotherapy Platform
Werewolf Therapeutics is a clinical-stage biopharmaceutical company developing conditionally activated immune therapies for cancer and other immune-mediated diseases. Its technology is designed to stimulate immunity more selectively in disease tissue, with the goal of reducing the systemic toxicity that has limited conventional proinflammatory immune therapies.
PREDATOR, INDUKINE, and INDUCER Programs
The company's PREDATOR platform supports two related drug design approaches. INDUKINE molecules are engineered cytokines intended to remain inactive in peripheral tissue and activate preferentially in the tumor microenvironment. INDUCER molecules build on the same conditional activation logic but are directed toward immune stimulation against tumor-associated targets.
Clinical Cytokine Assets
Werewolf's most advanced clinical candidates are WTX-124 and WTX-330, systemically delivered and conditionally activated IL-2 and IL-12 INDUKINE molecules for solid tumors. These programs anchor the company's clinical-stage oncology profile and provide the key data readouts for validating whether conditional cytokine activation can improve therapeutic index.
Strategic Alternatives and Platform Optionality
Werewolf sold the JZP898 program to Jazz Pharmaceuticals and used the proceeds to repay its K2 HealthVentures loan. The company is now evaluating strategic alternatives with Piper Sandler while continuing to support its INDUKINE and INDUCER programs. This makes Werewolf a platform company with meaningful scientific optionality but also a near-term strategic-decision overhang.
Future catalysts
Clinical data updates for WTX-124 and WTX-330 expected in the second half of 2026.
Recent news
- 01
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Source: Werewolf Therapeutics
- 02
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Source: Werewolf Therapeutics
- 03
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Source: Werewolf Therapeutics
- 04
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
Source: Werewolf Therapeutics
- 05
Werewolf Therapeutics Announces Pipeline and Business Updates
Source: Werewolf Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Werewolf Therapeutics (HOWL)?
Werewolf Therapeutics (HOWL) most recently closed at 0.40 USD, a +0.20% move versus the previous session.
What is the market cap of Werewolf Therapeutics (HOWL)?
Werewolf Therapeutics currently has a market capitalization of 20.9M USD on BioPharmSignal.
What does Werewolf Therapeutics do?
Conditionally Activated Immunotherapy Platform Werewolf Therapeutics is a clinical-stage biopharmaceutical company developing conditionally activated immune therapies for cancer and other immune-mediated diseases. Its technology is designed to stimulate immunity more selectively in disease tissue, with the goal of reducing the systemic toxicity that has...
On which exchange is HOWL stock listed?
Werewolf Therapeutics (HOWL) is associated with NASDAQ, United States, Biopharma.
What is WTX-124?
Clinical data updates for WTX-124 and WTX-330 expected in the second half of 2026.
Which conditions is Werewolf Therapeutics targeting with WTX-124?
Werewolf Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Werewolf Therapeutics describe recent progress with WTX-124?
Clinical data updates for WTX-124 and WTX-330 expected in the second half of 2026.
What is WTX-330?
Clinical Cytokine Assets Werewolf's most advanced clinical candidates are WTX-124 and WTX-330, systemically delivered and conditionally activated IL-2 and IL-12 INDUKINE molecules for solid tumors.